BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Sacituzumab Govitecan-hziy: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Gilead Sciences. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Gilead Sciences GILDNCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Metastatic Breast Canceractive not recruiting331
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P2Gilead Sciences GILDNCT05119907 Study of Sacituzumab Govitecan in Patients With Solid TumorSolid Tumoractive not recruiting53

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.